Vargas Andrew, Kim Hwa Sun, Baral Erika, Yu Wan-Qing, Craft Cheryl Mae, Lee Eun-Jin
Mary D. Allen Laboratory for Vision Research, USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, California, United States of America.
Department of Biological Structure, University of Washington, Seattle, Washington, United States of America.
PLoS One. 2017 Aug 2;12(8):e0182389. doi: 10.1371/journal.pone.0182389. eCollection 2017.
Retinitis Pigmentosa (RP) begins with the death of rod photoreceptors and is slowly followed by a gradual loss of cones and a rearrangement of the remaining retinal neurons. Clusterin is a chaperone protein that protects cells and is involved in various pathophysiological stresses, including retinal degeneration. Using a well-established transgenic rat model of RP (rhodopsin S334ter), we investigated the effects of clusterin on rod photoreceptor survival. To investigate the role of clusterin in S334ter-line3 retinas, Voronoi analysis and immunohistochemistry were used to evaluate the geometry of rod distribution. Additionally, immunoblot analysis, Bax activation, STAT3 and Akt phosphorylation were used to evaluate the pathway involved in rod cell protection. In this study, clusterin (10μg/ml) intravitreal treatment produced robust preservation of rod photoreceptors in S334ter-line3 retina. The mean number of rods in 1mm2 was significantly greater in clusterin injected RP retinas (postnatal (P) 30, P45, P60, & P75) than in age-matched saline injected RP retinas (P<0.01). Clusterin activated Akt, STAT3 and significantly reduced Bax activity; in addition to inducing phosphorylated STAT3 in Müller cells, which suggests it may indirectly acts on photoreceptors. Thus, clusterin treatment may interferes with mechanisms leading to rod death by suppressing cell death through activation of Akt and STAT3, followed by Bax suppression. Novel insights into the pathway of how clusterin promotes the rod cell survival suggest this treatment may be a potential therapeutic strategy to slow progression of vision loss in human RP.
视网膜色素变性(RP)始于视杆光感受器的死亡,随后视锥细胞逐渐缓慢丧失,剩余的视网膜神经元也会重新排列。簇集蛋白是一种伴侣蛋白,可保护细胞并参与包括视网膜变性在内的各种病理生理应激反应。我们使用一种成熟的RP转基因大鼠模型(视紫红质S334ter),研究了簇集蛋白对视杆光感受器存活的影响。为了研究簇集蛋白在S334ter-line3视网膜中的作用,采用了沃罗诺伊分析和免疫组织化学方法来评估视杆分布的几何形状。此外,还使用免疫印迹分析、Bax激活、STAT3和Akt磷酸化来评估参与视杆细胞保护的途径。在本研究中,玻璃体内注射簇集蛋白(10μg/ml)可在S334ter-line3视网膜中显著保护视杆光感受器。在注射簇集蛋白的RP视网膜(出生后(P)30、P45、P60和P75)中,每平方毫米视杆的平均数量显著高于年龄匹配的注射生理盐水的RP视网膜(P<0.01)。簇集蛋白激活了Akt和STAT3,并显著降低了Bax活性;此外,还在穆勒细胞中诱导了磷酸化STAT3,这表明它可能间接作用于光感受器。因此,簇集蛋白治疗可能通过激活Akt和STAT3来抑制细胞死亡,进而抑制Bax,从而干扰导致视杆细胞死亡的机制。对簇集蛋白促进视杆细胞存活途径的新见解表明,这种治疗可能是减缓人类RP视力丧失进展的一种潜在治疗策略。